trial

In-Patient Study In Schizophrenic Patients

NCTId NCT00197093
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Completed
Enrollment 60
Sponsored by GlaxoSmithKline
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Completed
Enrollment
60
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2004-09
Primary completion
—
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
SB773812

Sponsors

GlaxoSmithKlineLead Sponsor

Sites

0 total

Facts & assertions

3 sourced
Enrollment
60
Phase
PHASE1
Status
COMPLETED
relationships
The graph out of here
drug
SB773812
drug
lead_sponsor
GlaxoSmithKline
company
indication
Schizophrenia
indication
Schizophrenia
indication